Forty years across the clinic, the lab, the C-suite, and intelligent machines.

Twelve years at AIIMS — from MBBS to the M.Ch. in Neurosurgery. Four more followed as a consultant neurosurgeon at VIMHANS in New Delhi, running three to five major procedures a week with a particular interest in spinal surgery and minimally invasive endoscopy and stereotaxy.

The clinic is where everything else in this career is anchored. It sets the bar for what "well-made" means, and it is the ground truth that every later layer — science, management, technology — must answer to.

Research Instructor in the Department of Neurobiology and Anatomy at Drexel University College of Medicine. Two programmes: lumbar-puncture delivery of bone marrow stromal cells into injured cervical cord, and mechanically engineered hydrogel scaffolds for axonal growth.

Five peer-reviewed publications came out of this period. More durably, the lab trained the instinct that distinguishes a working model from a well-demoed one — an instinct that re-emerges when judging AI systems today.

Joined McKinsey & Company in New York, moved to Dubai, spent six years advising healthcare organisations through growth, turnaround, and regulatory change.

CEO of Max Healthcare (2011–2014), Managing Director and CEO of Manipal Hospitals (2014–2017), and CEO of Parkway Pantai India — IHH-India (2018–2019). Three of India's largest hospital networks, across a span that took each through material expansion and transition.

The C-suite years are where the operator's instinct is forged: what scales, what doesn't, what a board reads in the silence between two line items, and what governance looks like when an institution is under pressure.

Co-founded BuddhiMed Technologies (2019–2021), then NeuranceAI (2021–present) — a deep-technology company building intelligent machines inspired by the human brain, for critical healthcare problems. Also a co-founder of R-Tej Health Analytics.

Independent Director at Centre for Sight, NephroPlus, and Livasa Hospitals. Advisor to Novo Holdings' Asia Novo Advisor Group and to EQT Group. Earlier advisory roles with the National Health Authority of India and GenomSys (Switzerland).

Across each of these seats, the same discipline holds: sector depth before AI enthusiasm, governance before velocity, and the patient — or the clinician serving the patient — at the centre of every diligence.